BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson TM, Howard AH, Miller MA, Allen LL, Huang M, Molina KC, Bajrovic V. Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients. Open Forum Infect Dis 2021;8:ofab294. [PMID: 34262988 DOI: 10.1093/ofid/ofab294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Johnson TM, Molina KC, Howard AH, Schwarz K, Allen L, Huang M, Bajrovic V, Miller MA. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin Infect Dis 2021:ciab674. [PMID: 34665248 DOI: 10.1093/cid/ciab674] [Reference Citation Analysis]
2 Askar SF, Kenney RM, Tariq Z, Conner R, Williams J, Ramesh M, Alangaden GJ. Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients. J Pharm Pract 2022;:8971900221074929. [PMID: 35090351 DOI: 10.1177/08971900221074929] [Reference Citation Analysis]